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Hippocrates, the father of medicine, first recognised stroke 2400 years ago after 
noting that occlusion of the carotid arteries caused loss of consciousness.1 In the 
twenty-first century, stroke is ranked as the second leading cause of death with an 
estimated mortality of around 5.5 million in 2016.2 Additionally, over 50% of 
stroke survivors suffer chronic disability.3 Heart failure (HF) is a global cause of 
morbidity and mortality with an estimated 40 million cases in 2015.4 Long-term 
multi-system complications of HF (Figure 1) and multimorbid disease interactions 
are of increasing importance and demand a multidisciplinary approach. The pre-
valence of both stroke and HF is expected to increase due to an ageing 
population.5,6 It has thus far proven difficult to elucidate the strength of the 
association between HF and stroke. This is due to the presence of many confound-
ing factors in previous studies including but not limited to small sample sizes, 
heterogeneous study cohorts, differing definitions of stroke, multiple confounding 
factors and a short duration of follow up.7–12 The Framingham Study showed that 
HF was associated with a two to three times higher risk of stroke.13 However, 
patients with HF also have several co-morbidities which on their own have 
a propensity to cause ischaemic stroke, such as atrial fibrillation (AF), hypertension, 
ischaemic heart disease and diabetes.8,14 Lip et al, demonstrated that patients 
without AF or prior stroke in the study had a hazard ratio of 2.3 (95% 
Confidence interval (CI) 1.8–3.0) for ischemic stroke in patients with vs without 
incident heart failure.8 Abdul-Rahim et al reported that a clinical trial population of 
patients with HF with AF had a higher average annual incidence rate of stroke 
compared with patients with HF and without AF (1.6% vs 1.2%).15
The presumed aetiology of stroke in HF is likely to be secondary to augmenta-
tion of the Virchow’s triad: prothrombotic factors, endothelial injury and left 
ventricular thrombus formation with subsequent cerebral embolism.16,17 These 
vascular alterations are observed in both HF with reduced ejection fraction 
(HFrEF) as well as in HF with preserved ejection fraction (HFpEF). 
Prognostically, patients who suffer stroke and have HF as an existing comorbidity 
appear to have much greater rates of mortality. In this case, HF appears to add insult 
to injury.18,19
There have been several attempts to quantify the risk of stroke in HF with mixed 
results. A 2015 study looking at the CHA2DS2-VASc scoring system (a validated 
tool for AF patients) found that whilst the scoring system had a modest predictive 
accuracy in this cohort, the clinical utility itself was yet unclear.20 More recent data 
from a 2017 retrospective study has suggested that the CHA2DS2-VASc scoring 
system has similar validity in both an AF and a non-AF HF cohort of patients.9 The 
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prevention of stroke in this cohort is also unclear, with 
data from a meta-analysis of 4 randomized control trials 
with a total of 3681 patients comparing warfarin to aspirin 
demonstrating no difference in mortality. However, war-
farin conferred a lower stroke risk at the cost of a higher 
bleeding risk.21
In this issue, Tai and colleagues attempt to shed further 
light on the topic of the long-term risk of stroke and 
poststroke adverse outcomes in a HF population. There 
were 2 separate datasets studied:
1. Study 1–20,072 adults aged ≥30 years newly diag-
nosed with HF extracted from the Taiwan national 
health insurance programme between 2000 and 
2005. This group was compared against a cohort 
of 80,288 non-HF patients matched based on age 
and sex. Both groups had no history of stroke.
2. Study 2–480,604 adults aged ≥30 hospitalized for 
stroke with and without HF between 2002 and 
2009. In this cohort were 30,532 patients with 
a prior diagnosis of HF.
From their analysis, several important points of discussion 
emerge in study 1. Firstly, in the HF cohort, stroke risk 
was significantly higher (hazard ratio (HR) 2.32, 95% CI 
2.21–2.43). Secondly, this increased risk of stroke was 
independent of age and medical background. Thirdly, the 
association between increased stroke risk was seen 
throughout the follow-up period when patients who devel-
oped stroke in the first 12 months (HR 1.72, 95% CI 
1.63–1.81) after the onset of HF were excluded. In study 
2, the main finding is that in the HF cohort there was 
a higher risk of poststroke pneumonia (Odds ratio (OR) 
1.31, 95% CI 1.24–1.38), sepsis (OR 1.25, 95% CI 
1.17–1.35), intensive care admission (OR 1.47, 95% CI 
1.41–1.54), and overall mortality during the hospitalisation 
(OR 1.44, 95% CI 1.31–1.59).
Tai et al’s study benefits from a large sample size and 
long duration of follow-up lending credible evidence to 
two emerging consensuses. Mainly, that HF is a strong risk 
factor for stroke and that stroke with underlying HF is 
much worse prognostically. The results reported are con-
sistent with multiple previous studies.7–11 Furthermore, 
this study demonstrates that stroke risk persists and does 
not normalise after 6 months, a finding that has previously 
been shown.8 Several limitations, most of which are 
acknowledged by the authors, must be considered when 
interpreting this data. First, this is a retrospective observa-
tional study and therefore open to unknown confounding 
factors which may explain these findings; second, misclas-
sification is common in data that relies on coding for 
diagnosis; third, the population studied is a mainly homo-
genous Taiwanese population, therefore these findings 
may not necessarily be replicated in other ethnicities.
In conclusion, the researchers’ findings highlight the 
complex nature of the link between HF and stroke and its 
negative prognostic implications, reflecting earlier study 
results and solidifying this link. Going forward, important 
future areas that need to be researched include 1) identifi-
cation and validation of an appropriate scoring system for 
stroke risk in HF to highlight low and high-risk patients, 
and 2) identification of appropriate prophylactic treatment 
to help reduce the stroke burden in this cohort.
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Figure 1 Non-cardiac complications of heart failure.
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